Federal regulators approved Johnson & Johnson’s (NYSE: JNJ) nasal spray Spravato as the first stand-alone therapy for adults with treatment-resistant depression.
The Food and Drug Administration’s decision, announced last week, allows Spravato to be used without requiring patients to take oral antidepressants as well. The FDA previously required combination use with…
Please login to read all 423 words.
